INT7568

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1992
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 4.63
Pain Relevance 4.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Crhr1) response to stress (Crhr1) signal transducer activity (Crhr1)
Anatomy Link Frequency
plasma 2
hypothalamus 1
pituitary 1
Crhr1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 11 100.00 Very High Very High Very High
withdrawal 18 99.56 Very High Very High Very High
Morphine 11 99.12 Very High Very High Very High
opiate 12 98.64 Very High Very High Very High
antidepressant 67 98.56 Very High Very High Very High
narcan 7 98.44 Very High Very High Very High
addiction 5 97.84 Very High Very High Very High
Locus ceruleus 3 97.40 Very High Very High Very High
noradrenaline 5 94.56 High High
depression 77 93.68 High High
Disease Link Frequency Relevance Heat
Stress 42 99.64 Very High Very High Very High
Urological Neuroanatomy 18 99.12 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super

9 99.08 Very High Very High Very High
Anxiety Disorder 3 98.16 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 1 98.02 Very High Very High Very High
Suicidal Behaviour 123 96.84 Very High Very High Very High
Opiate Addiction 2 96.12 Very High Very High Very High
Weight Loss 1 87.64 High High
Body Weight 1 87.44 High High
Depression 102 84.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, these results suggest that CRF1 antagonists can block the aversive stimulus effects of opiate withdrawal and may be potential therapeutic targets for opiate dependence.
Negative_regulation (block) of CRF1 associated with addiction, antagonist, opiate and withdrawal
1) Confidence 0.43 Published 2005 Journal Neuropsychopharmacology Section Abstract Doc Link 15138444 Disease Relevance 0.26 Pain Relevance 1.74
However, blockade of CRF1R significantly reduced morphine withdrawal-induced increases in plasma adrenocorticotropin levels.
Negative_regulation (blockade) of CRF1R in plasma associated with withdrawal and morphine
2) Confidence 0.42 Published 2010 Journal Mol. Pharmacol. Section Abstract Doc Link 20159948 Disease Relevance 0.36 Pain Relevance 1.48
Distally, CRFR1 is decreased in WKY rats following CRD but not OF stress without any apparent changes in SD rats.
Neg (not) Negative_regulation (decreased) of CRFR1 associated with stress
3) Confidence 0.40 Published 2010 Journal Neurogastroenterol. Motil. Section Abstract Doc Link 19807869 Disease Relevance 0.49 Pain Relevance 0.05
These observations indicate that both CRA1000 and CRA1001 are selective and competitive CRF1 receptor antagonists with potent anxiolytic- and antidepressant-like properties in various experimental animal models, perhaps through inhibition of CRF1 receptors.
Negative_regulation (inhibition) of CRF1 associated with antidepressant, antagonist and anxiety disorder
4) Confidence 0.37 Published 1999 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 10215672 Disease Relevance 0.15 Pain Relevance 0.39
In contrast, distal CRFR1 and CRFR2 levels were higher in MS rats but were significantly reduced post OF stress.
Negative_regulation (reduced) of CRFR1 associated with stress
5) Confidence 0.37 Published 2010 Journal Peptides Section Abstract Doc Link 20096320 Disease Relevance 0.29 Pain Relevance 0.07
The 3 drugs decreased corticotropin-releasing hormone mRNA levels by 30-48% in the paraventricular nucleus of the hypothalamus.
Negative_regulation (decreased) of corticotropin-releasing hormone in hypothalamus
6) Confidence 0.27 Published 1992 Journal Brain Res. Section Abstract Doc Link 1351783 Disease Relevance 0.48 Pain Relevance 0.71
In addition, LPS increased corticosterone release, increased plasma intereleukin (IL)-1beta release, increased IL-1beta and IL-6 mRNA in hippocampus, increased corticotropin releasing hormone (CRH) mRNA in pituitary, and decreased CRH-1 mRNA in pituitary.
Negative_regulation (decreased) of CRH-1 mRNA in plasma
7) Confidence 0.18 Published 2005 Journal Psychopharmacology (Berl.) Section Body Doc Link 15565429 Disease Relevance 0.06 Pain Relevance 0
For example, in suicide victims, hypothalamus-pituitary-adrenal axis hyperactivity has been linked with elevated corticotrophin-releasing hormone levels in the cerebrospinal fluid, reduced corticotrophin-releasing hormone binding sites in the frontal cortex, augmented pro-opiate-melanocortic RNA density in the pituitary, large corticotrophic cell size, and alterations in the mineralocorticoid to glucocorticoid receptor messenger RNA (mRNA) ratio in the hippocampus of suicide victims.71–76 Also, a consistent association has been found between subsequently completed suicide and nonsuppression of cortisol in the dexamethasone suppression test.77–82
Negative_regulation (reduced) of corticotrophin-releasing hormone in pituitary associated with suicidal behaviour, urological neuroanatomy, hippocampus, opiate, attention deficit hyperactivity disorder and dexamethasone
8) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732010 Disease Relevance 1.77 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox